This paper evaluates patient-specific quality assurance (PSQA) in the treatment of small and multiple tumors by the CyberKnife system with fixed collimators, using an ion chamber and EBT3 films. We selected 49 patients with single or multiple brain tumors, and the treatment plans include one to four targets with total volumes ranging from 0.12 cc to 3.74 cc. All PSQA deliveries were performed with a stereotactic dose verification phantom. The A16 microchamber (Standard Imaging, WI, USA) and Gafchromic EBT3 film (Ashland ISP Advanced Materials, NJ, USA) were inserted into the phantom to measure the point dose of the target and the dose distribution, respectively. The film was scanned 1 hr after irradiation by a film digitizer scanner and analyzed using RIT software (Radiological Imaging Technology, CO, USA). The acceptance criteria was <5% for the point dose measurement and >90% gamma passing rate using 3%/3 mm and relative dose difference, respectively. The point dose errors between the calculated and measured dose by the ion chamber were in the range of −17.5% to 8.03%. The mean point dose differences for 5 mm, 7.5 mm, and 10 mm fixed cone size was −11.1%, −4.1%, and −1.5%, respectively. The mean gamma passing rates for all cases was 96.1%. Although the maximum dose distribution of multiple targets was not shown in the film, gamma distribution showed that dose verification for multiple tumors can be performed. The use of the microchamber and EBT3 film made it possible to verify the dosimetric and mechanical accuracy of small and multiple targets. In particular, the correction factors should be applied to small fixed collimators less than 10 mm.
Introduction
CyberKnife M6 (Accuray Inc, Sunnyvale, CA) is frameless and Image-guided robotic radiosurgery system (Fig. 1) . It has almost 1000 monitor unit (MU)/min high dose-rate and 6 MV flattening filter free treatment beam with noncoplanar beam geometry. It is suitable to treat for stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) for small and multiple brain tumors. It provides three types of collimator: fixed collimator, IRIS TM variable aperture collimator, and InCise TM 2 multileaf collimator (MLC).
1)
The IRIS TM collimator that allows the field size to be varied during treatment is applicable to a target that may not be spherical in shape requiring multiple collimator sizes. MLC can be considered for multiple brain tumors because fields are shaped to match the tumor closely and the delivery time is reduced. However, due to a limit of leaf width (3.85 mm), it is hard to cover the small size tumor and small 2, 3) For target coverage, the fixed collimator can be a useful modality but it is challenging when patientspecific quality assurance (PSQA) is performed because of lateral electronic disequilibrium, steep dose gradients, and complex dose distribution generated by multi-directional beams. 4, 5) To overcome these issues, we focus on PSQA for multiple brain tumors with small circular photon beams of diameter 5 to 25 mm in CyberKnife with a fixed collimator.
In this study, PSQAs were performed with the stereotactic dose verification phantom (SDVP; Standard Imaging, WI, USA), which includes the Exradin A16 microchamber 6) (Standard Imaging, WI, USA) and Gafchromic EBT3 film (Ashland ISP Advanced Materials, NJ, USA). was created by using a single fixed collimator only.
Materials and Methods
The accuracy of planning and delivery was evaluated by delivering treatment plans to the SDVP. As Fig. 2 , the A16 microchamber (0.007 cm 3 ) 6) and Gafchromic EBT3 film were inserted into the phantom to measure the central dose of the target and relative dose distribution, respectively. EBT3 film was cut by using Laser cutting system. 7) The 4 gold fiducial markers within the SDVP phantom were used for matching between live digitally reconstructed radiographs (DRRs) and DRRs created by planning CT images.
The active volume of the ionization chamber was located 
Radiochromic EBT3 films and digitization
Gafchromic self-developing EBT3 films are widely used for the dosimetric verification of treatment planning systems and more generally for the QA of linear accelerators.
EBT3 films have a high spatial resolution (~25 um) recommended for the quality control of small fields and highgradient dose distributions.
To correctly evaluate the gamma analysis, we made the film calibration curve representing the relationship between dose and intensity in the range of 0.1 Gy to 18 Gy.
The absolute dose was measured using Farmer chamber at 5 cm depth from the phantom surface (Fig. 3a) . EBT3 Films were then irradiated within a solid water slab phantom at 5 cm depth at source-to-surface distance (SSD) of 100 cm by using a 6 MV photon (Fig. 3b) . The EBT3 film was scanned and digitized 1 hr after irradiation by the Vidar scanner and analyzed using RIT software (Radiological Imaging Technology, CO, USA). The digitized pixel value was the range of 0-2 16 −1. To consider the measurement uncertainty, the calibration curve was fitted by an exponential function (Fig.   3c ).
PSQA plan and acceptance criteria
We used MultiPlan 5. The gamma analysis was conducted for all CyberKnife plans. Acceptance criteria for dosimetric accuracy were ≤±5% for the point dose measurement and ≥90% gamma passing rate using 3%/3 mm, applied 10% threshold dose, respectively.
8 Carlo simulation of A16 microchamber in CyberKnife M6, 9) we corrected the measured dose by applying 1.099, 1.025, and 1.013 for fixed cones of 5.0 mm, 7.5 mm, and 10.0 mm, respectively. When these correction factors were applied to fixed cones of 5 mm, 7.5 mm, and 10.0 mm, the range of the point dose error was significantly decreased as −4.8%, −2.2% and −0.7%, respectively. Thereby, the point dose error were within ±5% of tolerance and failed plans were only a few percentages outside tolerance.
The dose distribution of multiple tumors had patterns depending on the number and position of targets (Fig. 5a ).
Dose distribution for multiple tumors can be confirmed in the film plane (Fig. 5b) . Although the maximum dose of the target did not appear on the film, the gamma distribution in the film made it possible to verify the dose and beam direction for multiple tumors. In Fig. 6 , we analyzed the gamma passing rate for the size of the fixed collimator and the number of tumors. The mean gamma passing rates for all cases was 96.1%. Based on results, gamma passing rate was not dependent on the size of fixed collimator and number of tumors.
Discussion
PSQA was used to confirm that the Cyberknife plan was delivered correctly. For brain tumors, fixed collimators were used to achieve high target coverage. In this study, we observed that the point dose measured through the chamber was underestimated by the collimator size. Therefore, it is necessary to apply a correction factor to the volume of ion chamber and fixed collimator in case of small size tumors. Previous studies have reported that a correction factor using a single fixed collimator can be applied to a point dose measurement, but composite collimators cannot be applied. 11) Our CyberKnife plan used only one fixed collimator. It allowed us to implement a correction factor to adjust the point dose measured with the A16 ion chamber. As a result of applying the correction factor, we confirmed that the point dose error of CyberKnife plan was within ±5%.
As a result of gamma evaluation using EBT3 film, we found that most plans have a gamma passing rate of over 90%. We also confirmed that the fixed collimator size or the number of target is independent of gamma passing rate. It affirmed that PSQA using A16 microchamber and EBT3 film is sufficient to verify the accuracy of the delivery.
Conclusion
We have demonstrated that SDVP including microchamber and EBT3 film can be considered as PSQA to ensure the dosimetric and mechanical accuracy of small and multiple targets in CyberKnife with fixed collimators. In particular, the correction factors for A16 microchamber should be applied to the small fixed collimators less than 10 mm.
